Y Gelders

1.1k total citations
23 papers, 906 citations indexed

About

Y Gelders is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Y Gelders has authored 23 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 9 papers in Pharmacology and 5 papers in Clinical Psychology. Recurrent topics in Y Gelders's work include Schizophrenia research and treatment (10 papers), Treatment of Major Depression (5 papers) and Synthesis of Organic Compounds (4 papers). Y Gelders is often cited by papers focused on Schizophrenia research and treatment (10 papers), Treatment of Major Depression (5 papers) and Synthesis of Organic Compounds (4 papers). Y Gelders collaborates with scholars based in Belgium, France and Portugal. Y Gelders's co-authors include A. Reyntjens, S. Heylen, Mieke Hoppenbrouwers, Paul A. J. Janssen, Philip Burton, Paul Janssen, J. Heykants, R. Woestenborghs, C. J. De Ranter and Kenneth D. Roose and has published in prestigious journals such as The British Journal of Psychiatry, Psychopharmacology and Schizophrenia Research.

In The Last Decade

Y Gelders

23 papers receiving 829 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Y Gelders Belgium 12 503 455 217 178 91 23 906
Javaid I. Javaid United States 17 256 0.5× 245 0.5× 195 0.9× 100 0.6× 85 0.9× 34 727
S Gershon United States 17 369 0.7× 319 0.7× 143 0.7× 165 0.9× 73 0.8× 59 842
Gregory Sathananthan United States 14 370 0.7× 334 0.7× 128 0.6× 162 0.9× 101 1.1× 18 820
P Deniker France 17 435 0.9× 222 0.5× 145 0.7× 155 0.9× 137 1.5× 113 980
Don Goff United States 10 596 1.2× 471 1.0× 300 1.4× 195 1.1× 119 1.3× 13 1.3k
C Scharfetter Switzerland 14 367 0.7× 221 0.5× 114 0.5× 153 0.9× 203 2.2× 48 833
Joseph C. Schoolar United States 16 253 0.5× 266 0.6× 153 0.7× 112 0.6× 117 1.3× 41 873
Vincent Caillard France 11 436 0.9× 201 0.4× 77 0.4× 332 1.9× 62 0.7× 20 806
Shaun Jordan United States 14 463 0.9× 589 1.3× 298 1.4× 196 1.1× 92 1.0× 18 1.2k
Marie‐France Poirier France 17 412 0.8× 195 0.4× 116 0.5× 168 0.9× 221 2.4× 34 964

Countries citing papers authored by Y Gelders

Since Specialization
Citations

This map shows the geographic impact of Y Gelders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y Gelders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y Gelders more than expected).

Fields of papers citing papers by Y Gelders

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y Gelders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y Gelders. The network helps show where Y Gelders may publish in the future.

Co-authorship network of co-authors of Y Gelders

This figure shows the co-authorship network connecting the top 25 collaborators of Y Gelders. A scholar is included among the top collaborators of Y Gelders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y Gelders. Y Gelders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heylen, S. & Y Gelders. (1992). RISPERIDONE, A NEW ANTIPSYCHOTIC WITH SEROTONIN 5-HT2 AND DOPAMINE D2 ANTAGONISTIC PROPERTIES.. Clinical Neuropharmacology. 15. 180A–181A. 9 indexed citations
2.
Gelders, Y, et al.. (1990). Pilot Clinical Investigation of Risperidone in the Treatment of Psychotic Patients. Pharmacopsychiatry. 23(5). 206–211. 58 indexed citations
3.
Heylen, S. & Y Gelders. (1990). Combined serotonin 5-HT2 and dopamine D2 receptor antagonism in the treatment of schizophrenia. Schizophrenia Research. 3(1). 46–47. 1 indexed citations
4.
5.
Burton, Philip, et al.. (1989). Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology. 99(4). 445–449. 97 indexed citations
6.
Gelders, Y, et al.. (1989). The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis. Schizophrenia Research. 2(4-5). 411–415. 70 indexed citations
7.
Roose, Kenneth D., Y Gelders, & S. Heylen. (1989). Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration.. PubMed. 88(3). 233–41. 22 indexed citations
8.
Gelders, Y. (1989). Thymosthenic Agents, A Novel Approach in the Treatment of Schizophrenia. The British Journal of Psychiatry. 155(S5). 33–36. 89 indexed citations
9.
Gelders, Y. (1986). Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.. PubMed. 1 Suppl 1. 1–11. 7 indexed citations
10.
Reyntjens, A., et al.. (1986). Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin‐S2 receptor blocker. Drug Development Research. 8(1-4). 205–211. 151 indexed citations
11.
Gelders, Y, et al.. (1986). Ritanserin (R 55667) an original thymosthenic.. PubMed. 125(12). 136S–147S. 7 indexed citations
12.
Gelders, Y, et al.. (1985). Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology. 85(3). 329–332. 117 indexed citations
13.
Hoppenbrouwers, Mieke, et al.. (1985). The Influence of Ritanserin, a Serotonin Antagonist, in Anxiety Disorders: A Double-blind Placebo-controlled Study versus Lorazepam. Pharmacopsychiatry. 18(5). 303–305. 177 indexed citations
14.
Ansseau, Marc, et al.. (1984). Pilot study of a specific serotonergic antagonist, pirenperone, in the treatment of anxiety disorders.. PubMed. 83(5). 517–24. 19 indexed citations
15.
Parent, Marise B., et al.. (1982). [Pharmacokinetic of haloperidol decanoate in psychotic patients (author's transl)].. PubMed. 81(4). 399–406. 4 indexed citations
16.
Gelders, Y, et al.. (1982). 12-Month Study of Haloperidol Decanoate in ChronicSchizophrenie Patients. International Pharmacopsychiatry. 17(4). 247–254. 13 indexed citations
17.
Reyntjens, A., et al.. (1982). Pharmacokinetics of Haloperidol Decanoate. International Pharmacopsychiatry. 17(4). 238–246. 38 indexed citations
18.
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Javaid I. Javaid Breakdown of academic impact, for papers by S Gershon Breakdown of academic impact, for papers by Gregory Sathananthan Breakdown of academic impact, for papers by P Deniker Breakdown of academic impact, for papers by Don Goff Breakdown of academic impact, for papers by C Scharfetter Breakdown of academic impact, for papers by Joseph C. Schoolar Breakdown of academic impact, for papers by Vincent Caillard Breakdown of academic impact, for papers by Shaun Jordan Breakdown of academic impact, for papers by Marie‐France Poirier
Rankless by CCL
2026